MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

BioCryst Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

8.92 -0.89

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.87

Max

8.94

Belangrijke statistieken

By Trading Economics

Inkomsten

27M

32K

Verkoop

14M

146M

EPS

0

Winstmarge

0.022

Werknemers

580

EBITDA

22M

21M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+87.36% upside

Dividenden

By Dow Jones

Volgende Winsten

4 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

23M

1.9B

Vorige openingsprijs

9.81

Vorige sluitingsprijs

8.92

Nieuwssentiment

By Acuity

50%

50%

113 / 375 Rangschikking in Healthcare

BioCryst Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 jul 2025, 23:55 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6 jul 2025, 22:35 UTC

Acquisities, Fusies, Overnames

South32 Expects to Complete Transaction in Late 2025

6 jul 2025, 22:35 UTC

Acquisities, Fusies, Overnames

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6 jul 2025, 22:34 UTC

Acquisities, Fusies, Overnames

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5 jul 2025, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 15:57 UTC

Marktinformatie

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 jul 2025, 15:49 UTC

Marktinformatie

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole Received All Required Authorizations

4 jul 2025, 15:48 UTC

Acquisities, Fusies, Overnames

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 jul 2025, 15:47 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Agreement Was Announced on Dec. 19

4 jul 2025, 15:47 UTC

Acquisities, Fusies, Overnames

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 jul 2025, 15:46 UTC

Acquisities, Fusies, Overnames

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 jul 2025, 14:30 UTC

Acquisities, Fusies, Overnames

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 jul 2025, 13:53 UTC

Marktinformatie

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 jul 2025, 13:41 UTC

Marktinformatie

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 jul 2025, 13:41 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

4 jul 2025, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 12:37 UTC

Marktinformatie

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 jul 2025, 12:37 UTC

Marktinformatie

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Peer Vergelijking

Prijswijziging

BioCryst Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

87.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.75Ā USDĀ  87.36%

Hoogste 30Ā USD

Laagste 11Ā USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioCryst Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Sentiment

By Acuity

113 / 375 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.